← back to search

Sachin Agrawal

Jawaharlal Institute of Post Graduate Medical Education and Research · IN
Area of research
Epidemiology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Sepsis Diagnosis and Treatment, Liver Disease Diagnosis and Treatment, and Nutrition and Health in Aging.
h-index
18
citations
1,709
works
118
NIH funding
—
primary concept
Medicine
email
sachinagrawall@yahoo.co.in

Recent publications

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
Annals of Oncology 2021cited by 25position: lastdoi
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
Annals of Oncology 2018cited by 202position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Thomas Spires · Bristol-Myers Squibb (United States)1 papers (2021–2021)Luis Paz‐Ares · Zhejiang Cancer Hospital1 papers (2021–2021)— · 1 papers (2018–2018)Martin Reck · St. Luke's Clinic1 papers (2021–2021)David Balli · Bayer (United States)1 papers (2021–2021)— · 1 papers (2021–2021)K.H. Lee · Chungbuk National University Hospital1 papers (2021–2021)Gwénaëlle Gravis · University College London1 papers (2018–2018)Jeffrey Schneider · New York University1 papers (2018–2018)Georgina V. Long · ARC Centre of Excellence in Synthetic Biology1 papers (2018–2018)Phuong Tran · Northeast Ohio Medical University1 papers (2021–2021)Xiaochen Zhao · Xi'an University of Science and Technology1 papers (2018–2018)Suresh S. Ramalingam · Emory University1 papers (2021–2021)Jin Sun Lee · Centers for Disease Control and Prevention1 papers (2021–2021)— · 1 papers (2018–2018)William J. Geese · Bristol-Myers Squibb (United States)1 papers (2021–2021)Claus Garbe · STZ eyetrial1 papers (2018–2018)Scott S. Tykodi · Fred Hutch Cancer Center1 papers (2018–2018)Clarisse Audigier-Valette · Université de Toulon1 papers (2021–2021)Adam Płużański · National Institute of Oncology1 papers (2021–2021)